Valeria Rodríguez-Saenz

Valeria Rodríguez-Saenz

Auto-generated profile, based on publicly available information

Valeria Rodríguez-Saenz

Universidad de la República, Facultad de Medicina, Servicio de Oncología Clínica. Montevideo, Uruguay

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2024
Verified
Journal Article
Open access
NCNatalia Camejo
Natalia Camejo
CCCecilia Castillo-Leska
Cecilia Castillo-Leska
VRValeria Rodríguez-Saenz
Valeria Rodríguez-Saenz
GHGuadalupe Herrera-Álvarez
Guadalupe Herrera-Álvarez
DADahiana Amarillo-Hernández
Dahiana Amarillo-Hernández
GKGabriel Krygier-Waltier
Gabriel Krygier-Waltier
HER-2 positive (+) breast cancer (BC) accounts for 20-25% of BC, it is more aggressive, and it has a lower survival rate. Since the approval of trastuzumab in 1998, other HER-2-targeted therapies such as pertuzumab and trastuzumab emtansine (TDM1) have been introduced, improving patient survival. However, cardiotoxicity is an adverse effect of these treatments. To estimate the incidence of cardiotoxicity with trastuzumab, trastuzumab/pertuzumab, and TDM1 in women with HER-2 + BC treated over a 6-year period at the Hospital de Clínicas and the Hospital Departamental de Soriano. Observational, descriptive, and retrospective study which included patients with HER-2 + BC treated with trastuzumab, trastuzumab/pertuzumab, or TDM1. 81 patients were included, with a cardiotoxicity incidence of 23.4%. Cardiotoxicity was determined by a > 10% decrease in left ventricular ejection fraction (LVEF) (57.9%) and a LVEF < 50% evident during treatment (42.1%). Only 1 patient presented symptomatic heart failure. 63.1% of those who discontinued treatment due to cardiotoxicity managed to resume it. No relationship was evident between cardiovascular history or the administration regimen and the development of cardiotoxicity. The study showed a cardiotoxicity incidence similar to the international one. Most did not present cardiac toxicity, and if they did, it was asymptomatic and reversible.